Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Norfloxacin: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
9 October 2023
This article summarized the latest R&D progress of Norfloxacin, the Mechanism of Action for Norfloxacin, and the drug target R&D trends for Norfloxacin.
Latest Hotspot
4 min read
ELAHERE® Demonstrates Advantage in Overall and Progression-Free Survival in Ovarian Cancer
9 October 2023
ImmunoGen Inc. shared outcomes from two assessments of the MIRASOL Phase 3 trial. The trial evaluated safety and effectiveness of ELAHERE® in platinum-resistant ovarian cancer patients positive for the folate receptor alpha, versus chemotherapy.
Drug Insights
4 min read
Nizatidine Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target
9 October 2023
This article summarized the latest R&D progress of Nizatidine, the Mechanism of Action for Nizatidine, and the drug target R&D trends for Nizatidine.
Advanced Tech.
8 min read
Interpretation of Gene Therapy Company
9 October 2023
Gene Therapy Company focuses on correcting or compensating for diseases caused by abnormal genes by introducing foreign normal genes into target cells.
Drug Insights
4 min read
Unleashing the Power of Nitrazepam: A Comprehensive Review on R&D Breakthroughs, Action Mechanisms, and Drug Target
9 October 2023
This article summarized the latest R&D progress of Nitrazepam, the Mechanism of Action for Nitrazepam, and the drug target R&D trends for Nitrazepam.
Latest Hotspot
3 min read
MARIPOSA Phase 3 study hits key target, showing improved effectiveness of RYBREVANT® and Lazertinib versus Osimertinib for EGFR-Mut patients
9 October 2023
Landmark Phase 3 MARIPOSA Study achieves its main goal, demonstrating clinically relevant enhancement for RYBREVANT® and Lazertinib when compared to Osimertinib in EGFR-Mut patients.
Drug Insights
4 min read
A Comprehensive Review of Nimesulide's R&D Innovations and Drug Target Mechanism
9 October 2023
This article summarized the latest R&D progress of Nimesulide, the Mechanism of Action for Nimesulide, and the drug target R&D trends for Nimesulide.
Valuable Targets
5 min read
Analysis on the Clinical Research Progress of Akt inhibitors
9 October 2023
Akt, also known as protein kinase B, is a crucial enzyme that plays a significant role in various cellular processes within the human body.
Drug Insights
4 min read
Pharmaceutical Insights: Natamycin's R&D Progress and its Mechanism of Action on Drug Target
9 October 2023
This article summarized the latest R&D progress of Natamycin, the Mechanism of Action for Natamycin, and the drug target R&D trends for Natamycin.
Latest Hotspot
3 min read
Gracell Biotechnologies Announces Clinical Results for FasTCAR-T GC012F in High-Risk, Multiple Myeloma
9 October 2023
Gracell Biotechnologies has showcased updated long-term data from a continuing Phase 1 trial. This trial is assessing GC012F, a candidate for autologous CAR-T treatment that simultaneously targets CD19 and the B-cell maturation antigen (BCMA).
Drug Insights
4 min read
Exploring Moxidectine's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
9 October 2023
This article summarized the latest R&D progress of Moxidectine, the Mechanism of Action for Moxidectine, and the drug target R&D trends for Moxidectine.
Advanced Tech.
5 min read
Analysis on the Research Progress of Biosimilar Drugs
9 October 2023
Biosimilar drugs: These are therapeutic biological products that have similarity in quality, safety, and efficacy with a previously registered reference drug.